DUMAC Inc’s Syndax Pharmaceuticals SNDX Stock Holding History

DUMAC Inc’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-21,240	Closed	-$365K	–	33
2021 Q2	$365K	Buy	+21,240	New	+$389K	0.41%	22

Other funds holding SNDX

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DUMAC Inc's SNDX Position: Q3 2021 in Review

DUMAC Inc sold out of Syndax Pharmaceuticals (SNDX) in Q3 2021, closing a stake of 21,240 shares — an estimated $365K sold.

DUMAC Inc first reported a position in SNDX in Q2 2021 and held it in 1 quarter. The position peaked at $365K in Q2 2021. 123 funds tracked by Wall St. Rank hold SNDX as of Q3 2021.

DUMAC Inc reported no remaining Syndax Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
DUMAC Inc sold 21,240 Syndax Pharmaceuticals shares in Q3 2021, an estimated $365K.
DUMAC Inc first reported a position in Syndax Pharmaceuticals in Q2 2021 and held it in 1 quarter.
DUMAC Inc's Syndax Pharmaceuticals position peaked at $365K in Q2 2021.
123 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2021.

Based on DUMAC Inc's 13F filing for Q3 2021, filed 15 Nov 2021.